Cardiovascular Center, Division of Cardiology, Seoul National University Bundang Hospital, Seongnam, Korea.
Korean J Intern Med. 2020 May;35(3):487-497. doi: 10.3904/kjim.2020.120. Epub 2020 Apr 29.
Heart failure (HF) is a condition in which the heart is unable to pump enough blood to meet the body's needs for blood and oxygen. Thus, HF is a grave disease with high morbidity and mortality. Because the prevalence of and exposure to the risk factors for HF increase with age, the prevalence of HF has been increasing in an aging society, including Korea. The vast advancement of medical and device therapy has improved the outcomes of HF, but significant residual risk still exists, and the benefit is confined to patients with reduced ejection fraction. Finding effective treatment for HF with preserved ejection fraction and identification of groups who benefit from drug and device therapy remain challenging. In this review, we illustrate the epidemiology, temporal trends, and current status of medical and device therapy, including heart transplantation, as well as emerging treatments for HF in Korea and worldwide.
心力衰竭(HF)是一种心脏无法泵出足够的血液来满足身体对血液和氧气需求的疾病。因此,HF 是一种严重的疾病,具有高发病率和死亡率。由于 HF 的患病率和危险因素暴露随着年龄的增长而增加,HF 的患病率在包括韩国在内的老龄化社会中一直在增加。医学和设备治疗的巨大进步改善了 HF 的治疗效果,但仍存在显著的残余风险,而且获益仅限于射血分数降低的患者。寻找有效治疗射血分数保留的心衰以及确定从药物和设备治疗中获益的人群仍然具有挑战性。在这篇综述中,我们展示了韩国和全球 HF 的流行病学、时间趋势和目前的药物和设备治疗现状,包括心脏移植以及新兴治疗方法。